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Available online 18 March 2016Background:Microvascular damage of skin and internal organs is a hallmark of systemic sclerosis (SSc). Serum
uric acid (UA) represents a marker of inflammation and endothelial dysfunction. The aims of this study were
to evaluate the correlation between serum UA and intrarenal arterial stiffness evaluated by Doppler ultrasound
in SSc patients with normal renal function.We also evaluated the correlation between serum UA and other clin-
ical variables of the disease.
Methods: Forty-five SSc patients underwent clinical assessment, Doppler ultrasound of intrarenal arteries with
evaluation of resistive index (RI), pulsatile index (PI), and systolic/diastolic ratio (S/D), echocardiography with
systolic pulmonary artery pressure (PAPs), baseline pulmonary function tests, and nailfold videocapillaroscopy
(NVC). In all patients serum UA was measured.
Results: The serum UA showed a significant positive correlation with sCr (r = 0.33, p b 0.0001) and PAPs
(r = 0.38, p b 0.01) >and negative correlation with CKD-EPI (r =−0.35, p b 0.01). The mean value of serum
UA increased with severity of NVC damage. Using this cut-off value of 4.7 mg/dl, the mean value of Doppler in-
dices of intrarenal stiffness is significantly different (p b 0.05) in SSc patients with low normal or high normal
serum UA.
Conclusions: SerumUA concentration is higher in patients with highmicrovascular damage than in patients with
low microvascular damage. These preliminary data must be confirmed in large prospective studies.
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Uric acid
Systemic sclerosis
Renal Doppler ultrasound
Nailfold videocapillaroscopy
Systolic pulmonary artery pressure
microvascular damage
Endothelial dysfunctionIntroduction
Systemic sclerosis (SSc) is a connective tissue disease characterized
by endothelial dysfunction and fibrosis of both skin and internal organs.
Endothelial dysfunction, microvascular and macrovascular damage are
the hallmarks of SSc (Matucci-Cerinic et al., 2013).
The most important renal complication in SSc is scleroderma renal
crisis, but latent renal involvement is present such as isolated reduced
glomerular filtration rate (GFR), reduced renal functional reserve,
microalbuminuria and increased intrarenal arterial stiffness. A reduc-
tion of glomerular filtration rate (GFR) can be present in SSc patients
with normal serum creatinine (sCr) (Shanmugam and Steen, 2012). In
SSc patients, GFR can be evaluated by estimated GFR (eGFR). Gigante
et al. found that Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) equation provides more accurate eGFR in comparison to 7-Rome, Department of Clinical
Italy.
o).variable MDRD (Gigante et al., 2012). Increased arterial stiffness is
known to be associated with sclerodermic kidney dysfunction. It is
known that Doppler renal ultrasound is a useful and non-invasive diag-
nostic tool to evaluate intrarenal arterial stiffness. The Doppler indices
of intrarenal arterial stiffness showed a negative correlation with GFR
and they increase with the severity of microvascular damage of hands.
Elevated serum uric acid (UA) has been shown to be associated with
impaired endothelium-mediated relaxation, vascular stiffness (Sowers,
2013) and a restrictive left ventricular filling pattern or diastolic dys-
function (Hayden and Tyagi, 2004). Recently, the DETECT study has
been performedwith the aim of identifying predictors of pulmonary ar-
terial hypertension (PAH) in patients with SSc. Serum urate has not
been described previously as being predictive of PAH, but was identified
as such in this study where low values were associated with a low PAH
risk (Coghlan et al., 2013).
The aims of this study were to evaluate the correlation between
serum UA and intrarenal arterial stiffness evaluated by Doppler ultra-
sound in SSc patients with normal renal function. We also evaluated
the correlation between serum UA and other clinical variables of the
disease.
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Forty-five patients (36 female and 9 male; mean age 45 ±
13.8 years) fulfilling the American College of Rheumatology/European
League criteria for classification and diagnosis of SSc were enrolled in
this study (van denHoogen et al., 2013). Seventeen patients had limited
cutaneous SSc (lcSSc) and 28 presented diffuse cutaneous SSc (dcSSc) as
defined by LeRoy et al. (1998). Table 1 shows the SSc patients' epidemi-
ological and clinical features.
All SSc patients underwent treatmentwith calcium channel blockers
(nifedipine 30 mg/day). None of the patients were treated with immu-
nosuppressive agents (e.g. cyclophosphamide or mycophenolate mofe-
til), steroid, angiotensin-converting enzyme inhibitors (ACE-I),
angiotensin II receptor blockers, diuretics or xanthine oxidase inhibi-
tors. Patients with elevated serum creatinine (sCr), elevated blood
urea, urinary tract infections, abnormal urinary sediment, glomerulone-
phritis, kidney stones, anti-phospholipid-associated nephropathy, dia-
betes, cardiovascular diseases such as hypertension, myocardial
infarction, arrhythmias, heart failure, hyperlipidemia, coagulopathy,
obesity, scleroderma renal crisis or smokers were excluded.
The subjects'written consentwas obtained according to theDeclara-
tion of Helsinki and the study was approved by the ethics committee of
Sapienza University (IRB approval 3377/2014).
Laboratory parameters
Laboratory investigations included sCr (normal range: 0.5–0.9mg/dl),
blood urea nitrogen (normal range: 10.20–49.80 mg/dl), serum UA (nor-
mal range: 3.40–7.20 mg/dl), sodium, potassium, glucose, albumin, uri-
nalysis and 24 h proteinuria. sCr was measured using a Jaffe alkaline
picrate assay (Abbott Aeroset analyzer) (Wetzels et al., 2007). Serum
UA was measured with an automatic analyzer (7700 series; Hitachi,
Tokyo, Japan).
Calculation of GFR
GFRwas calculated using the CKD-EPI equation, already validated in
SSc patients (Gigante et al., 2012), expressed as a single equation:
GFR = 141 × min (sCr/k, 1) α × max (sCr/k, 1)-1.209 × 0.993Age ×
1.018 (if female) × 1.159 (if black), where k is 0.7 for females and 0.9
for males,α is−0.329 for females and−0.411 for males, min indicates
theminimumof sCr/k or 1 andmax indicates themaximumof sCr/k or 1
(Levey et al., 2009).
Nailfold videocapillaroscopy (NVC)
NVC was performed with a videocapillaroscope (Pinnacle Studio
Version 8) equipped with a 500× optical probe. The nailfold of theTable 1
SSc patients' epidemiological and clinical features.
Sex (female/male) 36/9
Age, years 45 ± 13.8
Disease duration, years 9 ± 6
DAI 3 ± 2
DSS 6 ± 3
dcSSc/lcSSc 28/17
SSc-specific autoantibodies n (%)
Anti-topoisomerase I 24 (53)
Anticentromere 13 (29)
None 8 (18)
Capillaroscopic pattern n (%)
Early 13 (28.9)
Active 12 (26.7)
Late 20 (44.4)
Disease Activity index (DAI); Disease Severity Scale (DSS); limited cutaneous
SSc (lcSSc); diffuse cutaneous SSc (dcSSc).second, third, fourth and fifth fingers was examined in each patient. Ac-
cording to Cutolo et al. patterns identified within the “SSc pattern” in-
clude: early, active and late. The NVC is the best technique to evaluate
microvascular damage in SSc patients (Cutolo et al., 2006).
Clinical assessment
Modified Rodnan total skin score (mRSS) was chosen as the most
used method to assess skin induration in SSc. It is determined at a stan-
dardized location of 17 different sites of the body with a standardized
pinchingmethod and it is scored from0 to 3 (Clements et al., 1995). Dis-
ease activity in SSc was measured using Disease Activity Index (DAI),
which consists of 10weighted variables: total skin score N14, scleroder-
ma, digital necrosis, arthritis, total lung capacity b80%, erythrocyte sed-
imentation rate (ESR) N30, hypocomplementemia and change in
cardiopulmonary, skin and vascular symptoms in the past month
(Valentini et al., 2001). Disease severity was measured by Medsger Dis-
ease Severity Scale (DSS). The original scale assessed disease severity in
9 organs or systems, namely general health, peripheral vascular, skin,
joint/tendon, muscle and gastrointestinal tract, lungs, heart and kid-
neys. Each organ/system is scored separately from 0 to 4 depending
on whether there is no, mild, moderate, severe or end-stage involve-
ment (Medsger et al., 1999).
Doppler ultrasound
SSc patients were placed for at least 15min before the Doppler ul-
trasound examination in a temperature-controlled room at
22 + 0.4 °C. The size of the left and right kidneys and the flow in
the aorta and renal arteries were evaluated to detect a morphologic
abnormality or renal artery stenosis. During the measurements, the
patients were supine and held their breath. Doppler ultrasound ex-
aminations were performed by the same senior nephrologist blinded
to the clinical features of the patient. Renal Doppler ultrasound was
performed using a Toshiba Aplio Ultrasound System SSA-790
equipped with a convex 3.5-MHz probe. Renal Doppler flow was ob-
tained in 3 different interlobar arteries of both kidneys (mesorenal,
superior, and inferior pole), guided by color-flow mapping. The
Doppler gate width was kept small, and the angle of insonation
was maintained at b60°. We used an anterior approach for detecting
the renal artery origin and an oblique, lateral approach for the inter-
mediate tract and intrarenal vessels. No aliasing was allowed in the
interlobar arteries while the following parameters were measured:
peak systolic velocity (PSV), end diastolic velocity (EDV), resistive
index (RI), pulsatile index (PI), and systolic/diastolic ratio (S/D). RI
was calculated as (peak systolic frequency shift- minimum diastolic
frequency shift)/peak systolic frequency shift and the PI was calcu-
lated as (peak systolic frequency shift)/minimum diastolic frequency
shift)/mean frequency shift. The PSV and EDV are expressed as cm/s.
The mean value of 3 measurements of interlobar arteries from each
kidney was calculated. For each patient, Doppler ultrasound param-
eters were calculated as the mean of measurements of both kidneys.
While performing the renal Doppler examination, the operator
evaluated the heart function. The Doppler examination was not per-
formed in SSc patients with arrhythmia or tachycardia or bradycar-
dia. Weighted kappa was used to evaluate the interrater reliability
by the same observer. The kappa values for RI and S/D were 0.971
and 0.975, respectively. The intrapatient coefficient of variation for
RI and S/D measurement was 1.3% and 1.4%, respectively. Calcium-
channel blocker therapy was discontinued 72 h before the Doppler
ultrasound (Rosato et al., 2012). The mean references value for nor-
mal RI in adults is determinate to be 0.60 ± 0.10, with 0.70 as the
upper limit of normal (Parolini et al., 2009). Patients receiving
iloprost therapy underwent Doppler examination the day before
the next infusion.
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Echocardiographywas performedwith an ultrasound Toshiba Ultra-
sound System (Tokyo, Japan) with a convex 2.5–3.5-MHz probe. All
echocardiographic data were recorded according to the guidelines of
the American Society of Echocardiography (ASE)[17]. PH was consid-
ered present when the systolic pulmonary artery pressure (PAPs)
value ≥40 mmHg (Mukerjee et al., 2004).
Baseline pulmonary function tests
Spirometric parameters of flows and volumes [(FEV1, forced expira-
tory volume in the 1st second), FVC (Forced vital capacity), FEV1/FVC)]
and single-breath carbon monoxide (CO) diffusing capacity (DLCO),
corrected for hemoglobin concentration, were recorded with a Quark
PFT 2 spirometer (Cosmed) and expressed according to the standards
recommended by theAmerican/EuropeanRespiratory Society. All spiro-
metric parameters are expressed as percentage of predicted (Abboud
and Sansores, 1996).
Statistical analysis
The results were expressed as mean and standard deviation (SD) or
median and range, as appropriate. Commercial software (SPSS version
22.0) was used for the statistical analysis. The coefficient of skewness
and the coefficient of kurtosis were used to evaluate the normal distri-
bution of data. Multiple regression analysis was applied to evaluate
the relationship between serum UA and the demographic and clinical
features [age, disease duration (first symptom after RP), mRSS, DAI,
DSS] and internal organ damage indices (creatinine, CKD-EPI, PAPs, PI,
RI, S/D, DLCO, FVC). Pearson product–moment correlation coefficient
(r) was used to test for an association between numerical variables.
Group comparisons were made by Student's unpaired 2-tailed t-test
or the Kruskal–Wallis test, as appropriate. P-values b0.05 were consid-
ered significant. A receiver operating characteristic (ROC) curve analysis
was performed to analyze the prognostic accuracy of serum UA.
Results
Table 2 showed the mean values of serum UA, sCr, CKD-EPI, PAPs,
Doppler ultrasound indices and pulmonary function tests. In the multi-
ple regression analysis the serum UA showed a significant positive cor-
relation with sCr (r = 0.33, p b 0.0001) and PAPs (r = 0.38, p b 0,01)
and negative correlation with CKD-EPI (r =−0.35, p b 0.01) (Fig. 1).
No significant correlation (p N 0.05) was observed between serum UA
and age, DAI, DSS, mRSS, PI, RI, S/D, DLCO, FVC.Table 2
The mean value of serum UA and sCr, CKD-EPI, PAPs, Doppler ultrasound indices
and pulmonary function tests in all SSc patients.
Serum UA (mg/dl) 4.24 ± 1.23
sCr (mg/dl) 0.75 ± 0.16
CKD-EPI (mil/min) 101 ± 18.9
Proteinuria (g/24 h) 0.13 ± 0.04
PI 1.26 ± 0.29
RI 0.64/0.06
S/D 3.02 ± 0.88
Systolic blood pressure (mmHg) 112 ± 9
Diastolic blood pressure (mmHg) 71 ± 6
PAPs (mmHg) 28 ± 5.4
DLCO (% of predicted) 70 ± 16
FVC (% of predicted) 92 ± 19
BMI 23 ± 3.2
Uric acid (UA); serum creatinine (sCr); Chronic Kidney Disease Epidemiology Col-
laboration (CKD-EPI); systolic pulmonary artery pressure (PAPs); pulsatile index
(PI); resistive index (RI); systolic/diastolic ratio (S/D); carbonmonoxide diffusing
capacity (DLCO); forced vitality capacity (FVC); Body mass index (BMI).Themean value of serum UAwas significantly (p b 0.0001) different
in three capillaroscopic groups: early 3.23 ± 0.70, active 3.86 ± 1.12
and late 5.14 ± 0.91 (Fig. 1). No significant (p N 0.05) difference of
serum UA was observed in SSc patients with dcSSc (4.3 ± 1.3) or
lcSSc (4.1 ± 1.1).
Using a cut-off value of 4.7mg/dlwe grouped the SSc patients in two
groups: patients with low-normal value of serum UA (≤4.7 mg/dl) and
with high-normal serum UA (N4.7 mg/dl). Themean value of serumUA
in the first group (n = 24) is 3.27 ± 0.70 (n = 24) and in the second
group it is 5.36 ± 0.55 (n = 21). The mean PAPs value was higher
(p b 0.01) SSc patients with high-normal serum UA than in those with
low-normal serum UA (30 ± 4 mmHg vs 26 ± 6 mmHg). The mean
value of Doppler indices of intrarenal stiffness are significantly different
(p b 0.05) in SSc patients with low-normal serum UA or high-normal
serum UA: PI was 1.13 ± 0.22 vs 1.40 ± 0.30, RI 0.62 ± 0.05 vs
0.66 ± 0.07, S/D 2.67 ± 0.47 vs 3.42 ± 1.06 (Table 2, Fig. 2). The ROC
curves (AUC,% and 95% CI) demonstrated a good accuracy of serum UA
for PAPs 73.7 (59.7–88.0, p b 0.01), PI 75.7 (61.3–90.1, p b 0.01), RI
71.3 (56.6–81.6, p b 0.05) and S/D 71.9 (56.6–87.6, p b 0.01). No signif-
icant difference of clinical variables was observed in the two groups of
patients (Table 3).
Discussion
In our study serum UA shows a positive correlation with sCr and
intrarenal arterial stiffness, conversely serum UA showed a negative
correlation with CKD-EPI. UA is the final oxidation product of purine
metabolism and it is excreted primarily by the kidney. The hyperurice-
mia frequently precedes the development of CKD. Various pathogenetic
mechanisms (obesity, metabolic syndrome and arterial hypertension)
might be involved in the pathogenesis of hyperuricemia (Johnson
et al., 2013).
In our study the serum UA showed a linear positive correlation with
PAPs. Several studies have demonstrated that increased serum UA con-
centration in patients with PAH correlates with a worse prognosis
(Bendayan et al., 2003). Serum UA represents a prognostic predictor in
PAH with connective tissue disease. The authors say that cytokine pro-
duction, inflammation and endothelial dysfunction, which are consid-
ered to be among the primary events during the progression of the
scleroderma-induced vasculopathy and fibrosis, can cause an increase
in serum UA concentrations (Njaman et al., 2007). Then, Dimitroulas
et al. have demonstrated that serum UA increased in proportion to the
functional capacity in SSc patients with PAH (Dimitroulas et al., 2011).
In the DETECT study serum UA represents one of the six non-
echocardiographic variables to evaluate individual risk of PAH develop-
ment in SSc patients. Hyperuricemia is considered a biomarker of renal
hemodynamic impairment (Susic et al., 2015). In patientswith essential
hypertension, the serum UA concentration correlated inversely with
renal blood and directly with renal vascular and total resistance. Hyper-
uricemia in patients with essential hypertension most likely reflects
early renal vascular involvement, especially, nephrosclerosis (Messerli
et al., 1980).
Our studies demonstrated that intrarenal vascular damage repre-
sents the first manifestation of renal damage in SSc patients. Intrarenal
arterial stiffness, evaluated by Doppler indices, is higher in SSc patients
than healthy controls. Doppler indices of intrarenal arterial stiffness
show a negative correlation with eGFR and they progressively increase
with severity of capillaroscopic damage (Gigante et al., 2015; Gigante
et al., 2014; Rosato et al., 2013; Rosato et al., 2012).
Until today there are no studies that have shown an association be-
tween microvascular damage of skin and increased serum UA. Many of
the severe internal organ complications of SSc are vascular (PAH, sclero-
derma renal crisis and reduction of GFR with increased of intrarenal ar-
terial stiffness). Structural vascular damage occurs in many vascular
districts and it contributes to pulmonary, renal, cardiac and gastrointes-
tinal complications. In laboratory animals, hyperuricemia was also able
Fig. 1. A) Positive linear correlation between serum uric acid and serum creatinine. B) Positive linear correlation between serum uric acid and systolic pulmonary artery pressure (PAPs).
C) Negative linear correlation between serum uric acid and Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. D) Value of serum UA in three nailfold
videocapillaroscopy (NVC) groups.
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development of both systemic and glomerular hypertension in associa-
tion with elevated renal vascular resistance and reduced renal blood
flow (Sanchez-Lozada et al., 2008; Sanchez-Lozada et al., 2005). Al-
though this is the first report on the association between endothelial
damage and serum UA in SSc patients, the important limitations ofFig. 2. A)Mean value of systolic pulmonary artery pressure (PAPs) in SSc patients with low-no
value of resistive index in patients with low normal serum level UA (≤4.7 mg/dl) and high northis study are represented by a limited number of patients, the absence
of validation cohort andweak correlations. The serumUA concentration
shows a good correlation with the capillaroscopic damage, with the
PAPs values and estimated glomerular filtration rate. The division of
the SSc population in the two cut-off was weakly significant and it
needs further study to assess its usefulness.rmal serum level UA (≤4.7 mg/dl) and high-normal serum level UA (≥4.7 mg/dl). B) Mean
mal serum level UA (≥4.7 mg/dl).
Table 3
Themean value of PAPs, Doppler ultrasound indices, pulmonary function tests and clinical
variables of disease in SSc patients with normal and high serum UA.
Low normal
serum UA
(n = 24)
High normal
serum UA
(n = 21)
p value
PAPs (mmHg) 26 ± 6 30 ± 4 b0.01
PI 1.13 ± 0.22 1.40 ± 0.30 b0.05
RI 0.62 ± 0.05 0.66 ± 0.07 b0.05
S/D ratio 2.67 ± 0.47 3.42 ± 1.06 b0.05
DLCO (% predicted) 67 ± 19 72 ± 14 N0.05
FVC (% predicted) 90 ± 20 94 ± 18 N0.05
mRSS 13 ± 6 13 ± 6 N0.05
DAI 3 ± 2 3 ± 2 N0.05
DSS 6 ± 3 6 ± 4 N0.05
Systolic pulmonary artery pressure (PAPs); pulsatile index (PI); resistive index (RI); sys-
tolic/diastolic ratio (S/D); carbon monoxide diffusing capacity (DLCO); forced vitality ca-
pacity (FVC); modified Rodnan skin score (mRSS); Disease Activity index (DAI); Disease
Severity Scale (DSS).
43A. Gigante et al. / Microvascular Research 106 (2016) 39–43In conclusion serumUA concentration is higher in patientswith high
microvascular damage than in patientswith lowmicrovascular damage.
These preliminary data must be confirmed in large prospective studies.
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